tiprankstipranks
Aequus Pharmaceuticals Inc (TSE:AQS)
TSXV:AQS

Aequus Pharmaceuticals (AQS) Stock Price & Analysis

14 Followers

AQS Stock Chart & Stats

Day’s RangeC$0 - C$0
52-Week RangeC$0.01 - C$0.06
Previous CloseC$0.03
Volume300.00
Average Volume (3M)252.47K
Market Cap
C$3.71M
Enterprise ValueC$4.09M
Total Cash (Recent Filing)C$286.89K
Total Debt (Recent Filing)C$667.16K
Price to Earnings (P/E)
Beta0.58
Aug 26, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding132,634,431
10 Day Avg. Volume76,794
30 Day Avg. Volume252,475
Standard Deviation0.23
R-Squared0.00224
Alpha-0.00882
Financial Highlights & Ratios
Price to Book (P/B)-1.11
Price to Sales (P/S)15.61
Price to Cash Flow (P/CF)N/A
P/FCF Ratio27.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

19.34%0.00%0.00%80.66%
19.34%
Insiders
0.00% Other Institutional Investors
80.66% Public Companies and
Individual Investors

AQS FAQ

What was Aequus Pharmaceuticals Inc’s price range in the past 12 months?
Aequus Pharmaceuticals Inc lowest stock price was C$0.01 and its highest was C$0.06 in the past 12 months.
    What is Aequus Pharmaceuticals Inc’s market cap?
    Currently, no data Available
    When is Aequus Pharmaceuticals Inc’s upcoming earnings report date?
    Aequus Pharmaceuticals Inc’s upcoming earnings report date is Aug 26, 2024 which is in 34 days.
      How were Aequus Pharmaceuticals Inc’s earnings last quarter?
      Currently, no data Available
      Is Aequus Pharmaceuticals Inc overvalued?
      According to Wall Street analysts Aequus Pharmaceuticals Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Aequus Pharmaceuticals Inc pay dividends?
        Aequus Pharmaceuticals Inc does not currently pay dividends.
        What is Aequus Pharmaceuticals Inc’s EPS estimate?
        Aequus Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Aequus Pharmaceuticals Inc have?
        Aequus Pharmaceuticals Inc has 132,634,430 shares outstanding.
          What happened to Aequus Pharmaceuticals Inc’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Aequus Pharmaceuticals Inc?
          Currently, no hedge funds are holding shares in TSE:AQS
          ---

          Aequus Pharmaceuticals Stock Smart Score

          10
          Unlock Smart Score
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10

          Technicals

          SMA
          Positive
          20 days / 200 days
          Momentum
          -37.77%
          12-Months-Change

          Fundamentals

          Return on Equity
          Trailing 12-Months
          Asset Growth
          13.46%
          Trailing 12-Months

          Company Description

          Aequus Pharmaceuticals Inc

          Aequus Pharmaceuticals Inc is a Canada based specialty pharmaceutical company. The firm's operating segments are Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. Aequus is developing a pipeline of products in neurology and psychiatry. The company's launched and pipeline products are Tacrolimus IR, Vistitan, AQS1304, AQS1303, and others.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          Helix BioPharma
          BioMark Diagnostics
          Medexus Pharmaceuticals Inc
          Popular Stocks
          ---
          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis